Details of Disease

General Information of Disease (ID: DISZ5ZJN)

• Disease Name: Allergic conjunctivitis
• Synonyms: Atopic conjunctivitis; allergic conjunctivitis (disease); allergic conjunctivitis; allergic form of conjunctivitis (disease)
• Disease Class: 9A60: Conjunctiva disorder
• Definition: Conjunctivitis due to hypersensitivity to various allergens.
• Disease Hierarchy:
  DISCCUFN: Eye allergy
  DISGOZ4P: Conjunctivitis
  DISH5PVV: Chronic conjunctivitis
  DISZ5ZJN: Allergic conjunctivitis
• ICD Code:
  ICD-11: ICD-11: 9A60.02
  ICD-10: ICD-10: H10.1
  Expand ICD-11: '9A60.02
  Expand ICD-10: 'H10.1
  Expand ICD-9: 204.0,372.0,372.14,995.3
• Disease Identifiers:
  MONDO ID: MONDO_0005642
  MESH ID: D003233
  UMLS CUI: C0009766
  MedGen ID: 3590
  HPO ID: HP:0007879
  SNOMED CT ID: 231854006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 11 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alcaftadine	DM5J1NH	Approved	Small molecular drug	[1]
Azelastine	DMXTMBJ	Approved	Small molecular drug	[2]
Emedastine	DM36LAJ	Approved	Small molecular drug	[3]
Epinastine	DMX0K3Q	Approved	Small molecular drug	[4]
Ketotifen	DM74XKS	Approved	NA	[5]
Levocabastine	DMMZPWT	Approved	Small molecular drug	[6]
lifitegrast	DM4WVC5	Approved	Small molecular drug	[7]
Nedocromil sodium	DM87MJX	Approved	Small molecular drug	[8]
Olopatadine	DMKMWQG	Approved	Small molecular drug	[9]
Oralair grasses	DMUUHK4	Approved	NA	[10]
Pemirolast	DML97WV	Approved	Small molecular drug	[11]

This Disease is Treated as An Indication in 10 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AC-170	DMXZ9T3	Phase 3	Small molecular drug	[12]
Olea europaea-containing vaccine	DMCSSS4	Phase 3	NA	[13]
Parietaria Judaica-containing vaccine	DMSXGJQ	Phase 3	NA	[14]
AC-150	DM7PI4V	Phase 2	Small molecular drug	[15]
AL-38583	DMYKUE5	Phase 2	NA	[16]
Depigoid birch pollen extract vaccine	DMPL66T	Phase 2	NA	[17]
Phleum pratense-containing vaccine	DMIMRHR	Phase 2	NA	[18]
T-1210	DMVQQY4	Phase 2	NA	[19]
Grass pollen-derived peptides	DMCT8K5	Phase 1/2	NA	[20]
Ragweed mix vaccine	DM67SCK	Phase 1	NA	[21]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
FOV1101	DMDF3TK	Discontinued in Phase 2	NA	[22]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
OPRX	DMYALWP	Investigative	Small molecular drug	[23]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CCL11	TTCF05Y	Limited	Biomarker	[24]
CCL5	TT9DWLC	Limited	Biomarker	[24]
IRF1	TT4TU3L	Limited	Biomarker	[25]
LCK	TT860QF	Limited	Biomarker	[26]

This Disease Is Related to 1 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
SOCS5	OTN1ABYR	Strong	Biomarker	[27]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7587).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7121).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7174).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7176).
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7206).
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1586).
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7533).
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7607).
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7249).
• [10] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7329).
• [12] ClinicalTrials.gov (NCT02132169) A Multi-Center Study Evaluating the Safety of AC-170 0.24%. U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT00831025) Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen. U.S. National Institutes of Health.
• [14] Anti-inflammatory effects of pre-seasonal Th1-adjuvant vaccine to Parietaria judaica in asthmatics. J Asthma Allergy. 2011;4:19-25.
• [15] ClinicalTrials.gov (NCT01134328) Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC Model. U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT01001091) AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation. U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT01591343) Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma.. U.S. National Institutes of Health.
• [18] ClinicalTrials.gov (NCT01682070) SUBLIVAC FIX Phleum Pratense DT/DRF. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT01344083) Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis. U.S. National Institutesof Health.
• [20] ClinicalTrials.gov (NCT00833066) Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis. U.S. National Institutes of Health.
• [21] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030164)
• [23] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [24] Mast-cell activation augments the late phase reaction in experimental immune-mediated blepharoconjunctivitis.Graefes Arch Clin Exp Ophthalmol. 2003 May;241(5):394-402. doi: 10.1007/s00417-003-0641-9. Epub 2003 Apr 4.
• [25] Differential expression and signaling of IFN-gamma in the conjunctiva between Lewis and Brown Norway rats.Microbiol Immunol. 2003;47(10):785-96. doi: 10.1111/j.1348-0421.2003.tb03436.x.
• [26] Ag-specific recognition, activation, and effector function of T cells in the conjunctiva with experimental immune-mediated blepharoconjunctivitis.Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4366-74. doi: 10.1167/iovs.02-1323.
• [27] The control of allergic conjunctivitis by suppressor of cytokine signaling (SOCS)3 and SOCS5 in a murine model.J Immunol. 2005 Oct 15;175(8):5489-97. doi: 10.4049/jimmunol.175.8.5489.